Results 21 to 30 of about 2,710 (195)

Comparison of Two Anesthetic Methods for Intravitreal Ozurdex Injection [PDF]

Journal of Ophthalmology, 2015
Purpose. To determine whether subconjunctival lidocaine injection maintains additional anesthetic effect during intravitreal Ozurdex injection.Methods. 63 patients who were diagnosed as central or branch retinal vein occlusion and planned to receive Ozurdex injection for macular edema were prospectively included in the study.
Altintas, Ozgul, Kocer, Cigdem Akdag, Ozkan, Berna, KARABAŞ, VEYSEL LEVENT, YÜKSEL, NURŞEN, PİRHAN, DİLARA   +5 more
openaire   +5 more sources

Misdirected ozurdex implant

Oman Journal of Ophthalmology, 2021
Ozurdex is one of the most commonly inserted intravitreal steroid implants in cases of posterior uveitis and recalcitrant macular edema in cases of diabetic retinopathy and vascular occlusions. Here we report accidental malpositioning of this implant in patellar fossa.
Amber Amar Bhayana, Suneel Kumar, Shorya Vardhan Azad   +2 more
openaire   +3 more sources

Wandering Ozurdex® implant [PDF]

Journal of Ophthalmic Inflammation and Infection, 2011
To report the behavior of intravitreal Ozurdex(®) implant in eyes with post-lensectomy-vitrectomy (PLV) aphakia.Retrospective chart review of three eyes with PLV aphakia (three patients with uveitis) who received intravitreal injection of Ozurdex(®) for cystoid macular edema (one eye), persistent inflammation (one eye), and ocular hypotony (one eye ...
Bansal, Reema, Bansal, Pooja, Kulkarni, Pandurang, Gupta, Vishali, Sharma, Aman, Gupta, Amod   +5 more
openaire   +2 more sources

Efficacy and safety profile of intravitreal dexamethasone implant versus antivascular endothelial growth factor treatment in diabetic macular edema: a systematic review and meta-analysis

Scientific Reports, 2023
To better understand the efficacy of intravitreal dexamethasone implant (Ozurdex) versus antivascular endothelial growth factor (anti-VEGF) treatment in patients with diabetic macular edema (DME). A systematic review and meta-analysis. The study included
Sheng-Chu Chi, Yi-No Kang, Yi-Ming Huang
doaj   +1 more source

Intravitreal slow-release dexamethasone alleviates traumatic proliferative vitreoretinopathy by inhibiting persistent inflammation and Müller cell gliosis in rabbits [PDF]

International Journal of Ophthalmology, 2023
AIM: To evaluate the effects of intravitreal slow-release dexamethasone on traumatic proliferative vitreoretinopathy (PVR) and Müller cell gliosis and preliminarily explored the possible inflammatory mechanism in a rabbit model induced by penetrating ...
Yi-Ming Zhao, Rong-Sha Sun, Fang Duan, Fang-Yu Wang, Yu-Jie Li, Xiao-Bing Qian, Jie-Ting Zeng, Yao Yang, Xiao-Feng Lin   +8 more
doaj   +1 more source

Topical Povidone Iodine 2.5% Versus 5% for Endophthalmitis Prophylaxis During Intravitreal Injections. [PDF]

J Ophthalmol
Purpose Topical povidone iodine (PI) has been shown to reduce the risk of endophthalmitis following intravitreal injections (IVIs). However, PI is a known ocular irritant and can result in significant eye discomfort. Currently, 5% PI is the most used concentration for ocular surface disinfection prior to IVI. 2.5% PI has been proposed as an alternative
Ajlan RS, Dalla S, Parikh RJ, Pfannenstiel MM, Champion MT, Rahman MA, Diaz FJ.   +6 more
europepmc   +2 more sources

Fractured dexamethasone implant (OZURDEX®) following intravitreal injection

Oman Journal of Ophthalmology, 2021
Dexamethasone implant (Ozurdex™) is a relatively safe medication with few adverse events can happen. We demonstrate clinical course and images of a rare case of fractured intravitreal Ozurdex™ implant that observed immediately following injection and its
Saud M Aljohani, Abdulaziz M Al-Shehri, Khalid R Al-Rubaie   +2 more
doaj   +1 more source

Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex®) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion

Clinical Ophthalmology, 2011
Annie Chan, Loh-Shan Leung, Mark S BlumenkranzDepartment of Ophthalmology, Stanford University School of Medicine, Stanford, CA, USAAbstract: Macular edema is a common cause of visual loss in patients with retinal vein occlusions.
Chan A, Leung LS, Blumenkranz MS
doaj   +1 more source

Anterior Chamber Migration of Ozurdex Implants

Turkish Journal of Ophthalmology, 2020
We present patient characteristics and follow-up results of cases with anterior chamber dexamethasone implant migration. The common feature of all six presented cases was vitrectomized eyes. Four of the patients had sutured intraocular lens (IOL) implantation due to complicated cataract surgery, one had combined retinal detachment surgery with sutured ...
Özcan Kayıkcıoğlu, Suzan Doğruya, Cansu Sarıgül, Hüseyin Mayalı, Emin Kurt   +4 more
openaire   +4 more sources

Secondary ocular hypertension as an adverse effect of treatment with intravitreal dexamethasone implant: A retrospective Swedish cohort study. [PDF]

Acta Ophthalmol
Abstract Purpose To evaluate the incidence and risk factors for secondary ocular hypertension (SOHT) following intravitreal dexamethasone implants (Ozurdex®) in patients with diabetic macular oedema (DME) and macular oedema secondary to retinal vein occlusion (RVO) in a Swedish cohort.
Abu Ishkheidem I, Breimer M, Kamal S, Zetterberg M, Al-Hawasi A, Grönlund MA.   +5 more
europepmc   +2 more sources